Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment.

Taiwan J Ophthalmol 2019 Oct-Dec;9(4):224-232. Epub 2019 Dec 13.

Macula, Vitreous and Retina Associates of Costa RIca, San José, Costa Rica.

Diabetic macular edema (DME) is the most common cause of moderate visual loss in diabetic patients. The current treatment of choice for center-involved DME is anti-vascular endothelial growth factor (VEGF) treatment. Most patients that undergo pharmacological inhibition with anti-VEGF agents need multiple monitoring visits that include optical coherence tomography imaging and multiple injections. Despite this intensive treatment, up to 60% of eyes will have persistent DME after six consecutive monthly injections of an anti-VEGF. Its sustainability over the long term has been questioned. Pars plana vitrectomy (PPV) by increasing the vitreous cavity oxygenation, relieving vitreomacular traction, and removing cytokines from the vitreous cavity may cause long-term resolution of DME without the aforementioned concerns in selected cases. Eyes with vitreomacular traction clearly benefit from PPV as the primary treatment. The role of PPV for eyes with DME without tractional elements is less clear and needs to be explored further.

Download full-text PDF

Source
http://dx.doi.org/10.4103/tjo.tjo_61_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947753PMC
December 2019

Publication Analysis

Top Keywords

primary treatment
8
diabetic macular
8
macular edema
8
vitreous cavity
8
vitreomacular traction
8
treatment diabetic
8
pars plana
8
plana vitrectomy
8
treatment
6
dme
5
injections anti-vegf
4
increasing vitreous
4
consecutive monthly
4
dme consecutive
4
anti-vegf sustainability
4
monthly injections
4
sustainability long
4
vitrectomy ppv
4
questioned pars
4
term questioned
4

Similar Publications

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Ophthalmol 2018 03;136(3):257-269

Palmetto Retina Center, Columbia, South Carolina.

Importance: Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks of anti-vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment.

Objective: To assess outcomes of DME persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1. Read More

View Article and Full-Text PDF
March 2018

Current treatment approaches in diabetic macular edema.

Authors:
Carsten H Meyer

Ophthalmologica 2007 ;221(2):118-31

Department of Ophthalmology, Philipps University, Marburg, Germany.

Purpose: To review current treatment approaches in diabetic macular edema (DME).

Methods: The underlying pathopathology, classifications and diagnostic examination techniques including fluorescein angiography, optical coherence tomography and stereoscopic biomicroscopy. Treatment modalities with focal or grid argon laser photocoagulation, pars plana vitrectomy with and without peeling of the inner limiting membrane (ILM), as well as intravitreal injections using triamcinolone acetonide or novel vascular endothelial growth factor (VEGF) inhibitors are described. Read More

View Article and Full-Text PDF
May 2007

Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy.

Ophthalmologica 2004 Nov-Dec;218(6):378-84

Augenpraxisklinik Dr. Jahn, Kempten, Deutschland.

Background: Diabetic macular edema (DME) is the leading cause of severe visual loss in patients with diabetic retinopathy. This is so despite the fact that argon laser photocoagulation of the macula (M-ALC) has been shown to be beneficial. Recently, it has been suggested that pars plana vitrectomy (PPV) can lead to the resolution of DME and stop the deterioration of central visual acuity. Read More

View Article and Full-Text PDF
January 2005

[Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].

Klin Monbl Augenheilkd 2011 Oct 13;228(10):910-4. Epub 2011 Oct 13.

Netzhaut- und Glaskörperchirurgie, Augenklinik der Goethe-Universität Frankfurt/Main.

Background: The aim of this work is to report the efficacy of a 1.5 mL core pars plana vitrectomy (cppV) combined with isovolumetric substitution with 1.25 mg bevacizumab and 8 mg triamcinolone for the treatment of diabetic macular edema (DME). Read More

View Article and Full-Text PDF
October 2011